Clinical Trial

A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat". These medicines are also known as the "study drugs". The aim of the study is to see what side effects freneslerbart, mevonlerbart, and REGN-2Cat may have and if they help reduce eye allergy symptoms caused by cat hair/dander compared with a placebo. The study is looking at several other research questions, including: * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) * How long the study drug effect lasts
Protocol Amendment History 3 changes
critical Recruitment opened 2026-08-13
notable Primary completion pushed: 2027-10-16 -> 2029-05-31 2026-08-13
minor Completion pushed: 2028-06-30 -> 2029-09-20 2026-08-13
Trial Details
NCT Number NCT07675811
Lead Sponsor Regeneron Pharmaceuticals
Conditions Allergic Conjunctivitis
Enrollment 570 participants
Start Date 2026-07-31
Primary Completion 2029-05-31 (estimated)
Study Completion 2029-09-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-12